Blair William & Co. IL Has $30.51 Million Position in Edwards Lifesciences Corporation $EW

Blair William & Co. IL decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 7.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 390,133 shares of the medical research company’s stock after selling 30,093 shares during the quarter. Blair William & Co. IL’s holdings in Edwards Lifesciences were worth $30,512,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jennison Associates LLC lifted its stake in shares of Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after buying an additional 2,576,383 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Edwards Lifesciences by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock valued at $491,673,000 after acquiring an additional 264,311 shares during the period. Nuveen LLC acquired a new stake in Edwards Lifesciences during the first quarter worth approximately $330,881,000. Invesco Ltd. boosted its holdings in shares of Edwards Lifesciences by 2.6% during the first quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock worth $310,773,000 after acquiring an additional 107,241 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Edwards Lifesciences by 5.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock valued at $287,140,000 after purchasing an additional 198,882 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on EW shares. Daiwa America raised Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. JPMorgan Chase & Co. lifted their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, July 25th. The Goldman Sachs Group reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. Canaccord Genuity Group raised their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a research report on Friday, July 25th. Finally, Royal Bank Of Canada lifted their price objective on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $87.06.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $75.17 on Friday. The firm has a 50 day moving average of $78.20 and a 200-day moving average of $76.08. Edwards Lifesciences Corporation has a 12 month low of $64.89 and a 12 month high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $44.13 billion, a PE ratio of 10.82, a PEG ratio of 3.64 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the business posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.